Nature Communications

TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial

2025-11-24

Full text

DOI https://doi.org/10.1038/s41467-025-65267-0